DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

28.33B

Market cap28.33B

Price-Earnings ratio

32.02

Price-Earnings ratio32.02

Dividend yield

—

Dividend yield—

Average volume

7.43M

Average volume7.43M

High today

$74.30

High today$74.30

Low today

$72.57

Low today$72.57

Open price

$74.30

Open price$74.30

Volume

3.74M

Volume3.74M

52 Week high

$89.98

52 Week high$89.98

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $73.45. The company's market cap stands at 28.33B, with a P/E ratio of 32.02.

As of 2026-06-03, DexCom(DXCM) stock has fluctuated between $72.57 and $74.30. The current price stands at $73.45, placing the stock +1.2% above today's low and -1.1% off the high.

The DexCom(DXCM)'s current trading volume is 3.74M, compared to an average daily volume of 7.43M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

DXCM News

MarketWatch 1d

DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch

...

Simply Wall St 1d

Assessing Dexcom Valuation After FDA Software Defect Recall And Investor Reaction

The FDA enforcement report on a software defect in several Dexcom (DXCM) CGM iOS and watchOS apps has pushed product reliability and recall risk to the foregrou...

Simply Wall St 3d

How Investors May Respond To DexCom Global App Recalls Over Delayed Glucose Alerts

In April 2026, Dexcom voluntarily initiated Class II global recalls of its G7, ONE and ONE+ iOS and watchOS CGM apps after an FDA enforcement report highlighted...

Analyst ratings

84%

of 31 ratings

Buy

83.9%

Hold

16.1%

Sell

More DXCM News

TipRanks 5d

Dexcom Shareholders Approve Board, Auditor and Compensation

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 6d

DexCom price target raised to $84 from $79 at Citi

Citi raised the firm’s price target on DexCom (DXCM) to $84 from $79 and keeps a Buy rating on the shares. The firm updated models in the medical technology spa...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.